BMO raises Celanese stock price target to $58 on cost cuts

BMO Capital increased its price target for Celanese (NYSE:CE) to $58 from $56, citing cost-cutting and cash generation. The firm expects higher estimates for 2027-2028 due to growth in engineered materials, despite challenges in the acetyl chain business. Celanese reported Q3 2026 earnings of $1.65 per share, beating estimates, but revenue fell short. Other analysts have also raised price targets.

Original reporting
Published Nov 9, 2026, 2:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 2:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$CE
Bullish
high confidence
Mentioned
$CE
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$CEBullishMed
01

Why it matters

Analyst upgrades suggest near‑term upside, but supply constraints could limit long‑term gains.

02

Market read

The upgrade adds fresh positive bias to CE, likely prompting short‑term buying.

03

What to watch

Potential headwinds from acetyl chain supply issues in 2027‑2028.

Relevance 7/10Novelty 7/10Timing: today

Background

Celanese reported mixed Q3 2026 results with earnings beat but revenue miss; analysts are revising outlooks.

Company-level read

Ticker impact

$CEBullishHigh confidence
Context

BMO raised its price target on Celanese to $58, citing cost cuts and higher earnings estimates.

Expected impact

upward pressure as investors price in the higher target

Evidence & confidence

The new target and bullish commentary provide fresh upside catalyst.

Market effects

Positive for engineered materials and specialty chemicals sector.

Limited to US-listed chemical stocks.

Modest, reflects broader cost‑cutting trends.

Counterpoint

Target may be overly optimistic if cost cuts underdeliver.

Key entities

  • Celanese Corp.

    US‑listed chemical manufacturer (NYSE:CE).

  • BMO Capital Markets

    Raised price target to $58.

Related articles

$CEMed

Celanese Corp (CE) Q3 2026 Earnings Call Highlights: 2027 Free Cash Flow Outlook

Celanese Corp (CE) reported Q3 2026 earnings, with CFO Chuck Kyrish highlighting $70M in cost savings this year and $30M-$40M expected in 2027. CEO Scott Richardson noted strong demand from AI data center build-outs driving growth in electronics. Q4 guidance includes a 6-7% volume decline in Engineered Materials and a $25M decline in acetyls. The company expects margin compression in Q4 due to methanol prices and other cost pressures.

$CEMedAI 8/10

Celanese Q3 Earnings Call Highlights

Celanese (NYSE: CE) expects restructuring costs to decrease by $30M-$40M in 2027 and additional cost savings of $30M-$40M in 2027. The company targets $150M in productivity improvements to offset inflation. Engineered Materials segment sees growth in electronics and healthcare, while automotive and nylon conditions remain mixed. Acetyl Chain faces margin compression due to outages and cost pressures.

$CEMed

Celanese (CE) Q3 2026 Earnings Call Transcript

Celanese (CE) reported Q3 2026 earnings, highlighting $100M in cost savings for 2027 and $700M-$800M in free cash flow. The company expects growth in electronics and healthcare segments to continue into 2027, while addressing potential capacity needs in downstream derivatives. Management discussed market dynamics in Asia and the impact of tariff changes on VAM. According to the company, they remain focused on productivity and targeted investments.

$CEMedAI 8/10

Celanese Q3 2026 slides: specialty focus drives margin gains

Celanese (NYSE:CE) reported Q3 2026 earnings with revenue of $2.56B, missing estimates, but EPS of $1.65 beat expectations. The company highlighted strong free cash flow of $461M and raised full-year guidance to $750M-$800M. Shares rose 3.86% to $49.79. Celanese is shifting focus to high-margin specialty applications in medical and electronics, driving margin expansion.

$CEHighAI 8/10

Why is Celanese stock rallying today?

Celanese (CE) stock rose 4.3% in pre-market trading after reporting Q3 adjusted EPS of $1.65, beating estimates. Revenue grew 6% YoY to $2.56B, missing slightly. The company raised its full-year 2026 EPS guidance to $6.00–$6.25. Analysts Mizuho and BofA increased price targets. The S&P 500 and NASDAQ showed mild gains.

$CEMed

Celanese: Q3 Earnings Snapshot

Celanese Corporation (CE) reported Q3 earnings of $74M, or $1.65 per share adjusted, exceeding analyst expectations of $1.52. Revenue was $2.56B, slightly below forecasts. The company expects full-year earnings of $6 to $6.25 per share.